Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
-
Eledon Pharmaceuticals to Participate in Guggenheim SMID Cap Biotech Conference
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
-
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
-
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
-
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation
-
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
-
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
-
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results